Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study  by Pinholt, M. et al.
Incidence, clinical characteristics and 30-day mortality of enterococcal
bacteraemia in Denmark 2006–2009: a population-based cohort study
M. Pinholt1,2, C. Østergaard1,2, M. Arpi1, N. E. Bruun3, H. C. Schønheyder4, K. O. Gradel5,6, M. Søgaard4,7 and J. D. Knudsen2 for
the Danish Collaborative Bacteraemia Network (DACOBAN)†
1) Department of Clinical Microbiology, Copenhagen University Hospital, Herlev Hospital, Herlev, 2) Department of Clinical Microbiology, Copenhagen University
Hospital, Hvidovre Hospital, Hvidovre, 3) Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital, Gentofte, 4) Department of Clinical
Microbiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, 5) Research Unit of Clinical Epidemiology, Institute of Clinical Research, University of Southern
Denmark, Odense, 6) Center for National Clinical Databases, South, Odense University Hospital, Odense and 7) Department of Clinical Epidemiology, Aarhus
University Hospital, Aarhus, Denmark
Abstract
Enterococci currently account for approximately 10% of all bacteraemias, reﬂecting remarkable changes in their epidemiology. However,
population-based data of enterococcal bacteraemia are scarce. A population-based cohort study comprised all patients with a ﬁrst episode
of Enterococcus faecalis or Enterococcus faecium bacteraemia in two Danish regions during 2006–2009. We used data collected prospectively
during clinical microbiological counselling and hospital registry data. We determined the incidence of mono- and polymicrobial bacteraemia
and assessed clinical and microbiological characteristics as predictors of 30-day mortality in monomicrobial bacteraemia by logistic
regression analysis. We identiﬁed 1145 bacteraemic patients, 700 (61%) of whom had monomicrobial bacteraemia. The incidence was 19.6/
100 000 person-years (13.0/100 000 person-years for E. faecalis and 6.6/100 000 person-years for E. faecium). The majority of
bacteraemias were hospital-acquired (E. faecalis, 45.7%; E. faecium, 85.2%). Urinary tract and intra-abdominal infections were the
predominant foci for the two species, respectively. Infective endocarditis (IE) accounted for 25% of patients with community-acquired
E. faecalis bacteraemia. Thirty-day mortality was 21.4% in patients with E. faecalis and 34.6% in patients with E. faecium. Predictors of 30-day
mortality included age, co-morbidity and hospital-acquired bacteraemia. In addition, intra-abdominal infection, unknown focus and high-level
gentamicin resistance were predictors of mortality in E. faecalis patients. E. faecium was associated with increased risk of mortality
compared with E. faecalis. The study emphasizes the importance of enterococci both in terms of incidence and prognosis. The frequency of
IE in patients with E. faecalis bacteraemia emphasizes the importance of echocardiography, especially in community-acquired cases.
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Introduction
Over the past two decades Enterococcus faecalis and Entero-
coccus faecium have become increasingly important pathogens
worldwide, especially due to hospital-acquired infections.
Enterococcus spp. are rated as the third leading cause of
hospital-acquired bacteraemia in the United States and account
for 9.4% of the bacteraemias [1]. Consistent with this, an
Italian multicentre study reported enterococci in 11.4% of all
bacteraemias during a 1-year survey [2]. Similarly, Danish
surveillance data demonstrated rising incidences of E. faecalis
and E. faecium bacteraemia, with increases from 2002 to 2009
of 51% and 201%, respectively [3,4]. Enterococci are gener-
ically resistant to all cephalosporins and clinical use of
carbapenems and ﬂuoroquinolones is not recommended as
ﬁrst-line treatment. In addition, acquired resistance to
penicillins, aminoglycosides and glycopeptides has increased
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(www.ecdc.europa.eu/en/activities/surveillance/EARS-Net).
The 30-day mortality of enterococcal bacteraemia is above
25% for vancomycin-susceptible strains [5–7] and above 45%
for resistant strains [5,8].
Prior studies of enterococcal bacteraemia have predomi-
nantly focused on the association between antimicrobial
resistance and outcome [8–12]. Few studies have distinguished
between hospital-acquired, community-acquired and health-
care-associated bacteraemia despite the fact that risk factors
for bacteraemia (intravascular devices and invasive medical
procedures) and risk of acquiring an infection with resistant
enterococci are different for patients with these modes of
acquisition [4].
The current changes in the epidemiology of enterococcal
infections have created a need for studies of enterococcal
bacteraemia that include information of clinical relevance. The
aim of this Danish population-based cohort study was to
determine the incidence of enterococcal bacteraemia during
the period 2006–2009. Further, we gave special attention to
monomicrobial bacteraemia to avoid the impact of other
pathogens on mortality and determined (i) clinical character-
istics of patients with hospital-acquired, community-acquired
and healthcare-associated bacteraemia and (ii) predictors of
30-day mortality according to species.
Methods
Setting
We conducted this population-based cohort study in the
North Denmark Region and the Capital Region of Denmark
between 2006 and 2009 (approximately 1 750 000 inhabitants;
1 450 000 were adults ( 16 years); this equals ~35% of the
Danish population). Patients admitted to a tertiary national
referral centre within the Capital Region were not included in
the study. The centre only had a limited local patient uptake.
The Danish National Health service provides tax-supported
healthcare for all residents, including free access to primary
care and public hospitals. Therefore, all acutely ill patients
were admitted to a public hospital in their region of residence.
All Danish residents have a unique personal identiﬁcation
number that permits individual-level linkage between health
administrative registries [13].
Identiﬁcation of patients
Clinical microbiological service. In the Capital Region the service
to hospitals was provided by the Departments of Clinical
Microbiology at Herlev and Hvidovre Hospitals and in the
North Denmark Region by the Department of Clinical
Microbiology at Aalborg Hospital. The blood culture systems
were either BACTEC (BD, Franklin Lakes, NJ, USA) (Herlev)
or BacT/Alert (bioMerieux, Marcy l’Etoil, France) (Hvidovre
and Aalborg). Clinicians were notiﬁed about positive blood
cultures by a physician from the Department of Clinical
Microbiology. At this contact antimicrobial therapy was
discussed taking consideration of the Gram strain report.
The second notiﬁcation occurred as soon as the identity of the
pathogen and the susceptibility pattern became available. The
physicians making the calls recorded pertinent information
(see below) in an electronic form integrated with the
laboratory information system (ADBakt, Ramsta, Sweden).
Bacteraemia research database. We identiﬁed all adult patients
( 16 years) with a ﬁrst episode of bacteraemia with
E. faecalis or E. faecium in a bacteraemia research database
holding all episodes of bacteraemia in the catchment
population since 2006. Besides demographic and microbio-
logical data, including antibiogram, the database includes
information on the focus of the bacteraemia, medical
speciality, origin of bacteraemia (community-acquired, hospital-
acquired or healthcare-associated) and empirical antimicrobial
therapy.
Microbiology. Enterococcus faecalis and Enterococcus faecium
were identiﬁed using conventional methods [14] or VITEK II
(bioMerieux). Minimum inhibitory concentrations (MICs) were
determined for penicillin, ampicillin, vancomycin and gentami-
cin by use of either E-test or VITEK II. MIC  256 mg/L was
recorded as high-level gentamicin resistant (HLGR). MIC
breakpoints refer to the standards according to EUCAST
(www.eucast.org).
Origin
The bacteraemic episode was considered hospital-acquired
when diagnosed  48 h after hospital admission [15]. A
bacteraemia diagnosed within 48 h of hospital admission was
considered to be community-acquired [15]. Patients with
community-acquired bacteraemia and regular hospital visits
(e.g. for haemodialysis or chemotherapy) or a hospital stay
during the 30 days prior to admission were considered as
having healthcare-associated bacteraemia [16,17].
Focus of infection
The probable focus of infection was conﬁrmed as follows: (i)
microbiologically conﬁrmed if an isolate indistinguishable from
the blood isolate was cultured from a clinically plausible site;
(ii) clinically conﬁrmed if there were signs and symptoms of a
compatible localized infection (infective endocarditis (IE),
deﬁnite or possible, was deﬁned in accordance with the
modiﬁed Duke criteria [18]); or (iii) unknown in cases not
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fulﬁlling the two categories above. Cases with two or more
probable foci were classiﬁed as having an unknown focus.
Empirical antimicrobial therapy
We deﬁned empirical antimicrobial therapy as the therapy
given not later than 24 h after the ﬁrst positive blood culture
was drawn. Treatment with benzyl-penicillin, ampicillin, piper-
acillin/tazobactam, vancomycin or linezolid was considered
appropriate if the enterococcal isolate was susceptible in vitro,
the dosage was adequate according to national recommenda-
tions and the patient received intravenous treatment.
Co-morbidity
Information on co-morbidity was obtained from the Danish
National Patient Registry (DNPR). The DNPR contains data on
all somatic inpatient contacts since 1977 and all somatic
outpatient and emergency room contacts since 1995, including
discharge diagnoses coded according to the International
Classiﬁcation of Diseases system. For each patient we used all
records in the DNPR prior to the current admission to
calculate the Charlson co-morbidity index (CCI) [19]. In this
prognostic index, 19 major disease categories (e.g. malignancy,
cardiovascular diseases and diabetes mellitus) are assigned a
score, with higher scores given to more severe diseases. We
deﬁned three co-morbidity levels: low (CCI = 0), medium
(CCI = 1–2) and high (CCI  3).
Mortality
We obtained data on mortality from the Danish Civil
Registration System, in which vital status, including all deaths
and emigrations, are registered and updated daily [13].
Follow-up started on the day the ﬁrst positive blood culture
was drawn and lasted for 30 days (or until death).
Statistical analysis
The incidence of bacteraemia was calculated by dividing the
number of incident cases with the catchment population on 1
July of that year in the Capital Region (the population who
belonged to the local uptake area of the National referral
centre were excluded) and in the North Denmark Region of
Denmark (Statistics Denmark, www.statbank.dk).
We used Student’s t-test and Fisher’s exact test to compare
means and categorical variables, respectively, and a logistic
regression model to examine predictors of 30-day mortality
and compute odds ratios (ORs) with 95% conﬁdence intervals
(95% CIs). We adjusted for a priori known predictors of
mortality in patients with enterococcal bacteraemia (age,
origin of bacteraemia, co-morbidity level, focus of infection
and antimicrobial therapy) in the exploratory multivariable
model.
All statistical analyses were performed with Stata, vs. 11.2
(StataCorp, College Station, TX, USA).
Results
Incidence
During the 4-year study period, 1145 patients were identiﬁed
with ﬁrst-time enterococcal bacteraemia; 700 (61%) had
monomicrobial bacteraemia. The overall incidence of entero-
coccal bacteraemia was 19.6/100 000 person-years (E. faecalis
13.0/100 000 person-years and E. faecium 6.6/100 000 per-
son-years) (Fig. 1). The annual incidence of E. faecalis and
E. faecium showed a rising trend, with increases of 33% and
61%, respectively.
Descriptive epidemiology of monomicrobial bacteraemia
During the study period, 457 monomicrobial bacteraemias
(65%) were caused by E. faecalis and 243 (35%) by E. faecium
(Table 1). Most patients with E. faecalis bacteraemia were
admitted to a medical ward (66%) and 30.9% of the patients
with E. faecium were admitted to the intensive care unit. The
majority of enterococcal bacteraemias were hospital-acquired
(E. faecalis 45.7% and E. faecium 85.2%) and 85% of the patients
had coexisting chronic diseases (CCI  1). Few patients
received appropriate antimicrobial therapy within the ﬁrst day
(E. faecalis, 17.7%; E. faecium, 7.4%).
Urinary tract infection was the most common focus of
E. faecalis bacteraemia in all three modes of acquisition (34.6–
41.7%) (Table 2). IE was the focus of infection in 13.3% of
patients with E. faecalis bacteraemia and the prevalence was
particularly high in the group with community-acquired
bacteraemia (25%). The most frequent focus of E. faecium
was intra-abdominal infection, with a high prevalence in all
three modes of acquisition (36.2–49.9%). The focus of
infection was unknown in 30% and 40% of the patients with
E. faecalis and E. faecium, respectively.
Ampicillin resistance in E. faecium was frequent (87.7%)
(Table 1). Also, HLGR strains were frequently present, being
more frequent in E. faecium (64.4%) than in E. faecalis (38.2%).
Conversely, resistance to vancomycin (<2%) was rare. The
frequency of resistant strains (HLGR enterococci and ampi-
cillin-resistant E. faecium) was much higher in hospital-acquired
and healthcare-associated bacteraemia compared with com-
munity-acquired bacteraemia (Table 2).
Infective endocarditis
Sixty-one patients with monomicrobial E. faecalis bacteraemia
were diagnosed with IE. The number of cases with IE doubled
from 11 in 2006 (0.8/100 000 person-years) to 22 in 2009
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 145–151
CMI Pinholt et al. Enterococcal bacteraemia in Denmark 147
(1.4/100 000 person-years). Men were over-represented
(78.7%) and most infections were community acquired (59%).
Age (median age 75 years, IQR 69–80 years) and distribution of
co-morbidity were similar to non-IE E. faecalis patients. None-
theless, we noticed that 29.5% had no coexisting chronic disease
(CCI = 0) prior to the acquisition of IE. All E. faecalis strains
that caused IE were susceptible to ampicillin and vancomycin.
Eighteen per cent were HLGR, similar to the frequency in
community-acquired bacteraemia (data not shown).
Mortality
The 30-day mortality was 21.4% among patients with mono-
microbial E. faecalis bacteraemia (Table 3). Increasing age,
co-morbidity, hospital acquisition, intra-abdominal infection,
unknown focus and HLGR strains were associated with
increased risk of mortality. Patients with IE had low 30-day
mortality (8.2%) but this was not signiﬁcantly different from
patients with urinary tract infections. Three-month and 1-year
mortality for E. faecalis IE were 16.4% and 27.9%, respectively
(data not shown).
The 30-day mortality among patients with monomicrobial
E. faecium bacteraemia was 34.6%. A burden of co-morbidity,
increasing age and hospital acquisition appeared to predict
mortality in patients with E. faecium bacteraemia (Table 4).
Further, we found increased risk of mortality in patients
with monomicrobial E. faecium bacteraemia compared with
patients with monomicrobial E. faecalis bacteraemia (OR 1.54
(1.02–2.32)) (Table S1).
Discussion
To our knowledge, this is the ﬁrst population-based study of
enterococcal bacteraemia. We found a rising trend in
incidence and an overall incidence of approximately 20/
100 000 person-years. In accordance with other studies the
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TABLE 1. Demographic, clinical and microbiological charac-
teristics of monomicrobial E. faecalis and E. faecium bacter-
aemia patients
Variable E. faecalis n (%) E. faecium n (%) p-value
Total 457 (100) 243 (100) –
Age median
[IQR]/mean [SD]a
75 [64–82]/71.8 [14] 69 [59–76]/67.2 [14] <0.001
Male 324 (70.9) 140 (57.6) <0.001
Speciality
Medicine 304 (66.5) 104 (42.8) <0.001
Surgery 117 (25.6) 64 (26.3) 0.860
Intensive care unit 36 (7.9) 75 (30.9) <0.001
Origin of bacteraemia
Community acquired 144 (31.5) 18 (7.4) <0.001
Hospital acquired 209 (45.7) 207 (85.2) <0.001
Healthcare associated 104 (22.8) 18 (7.4) <0.001
Charlson co-morbidity index
Index low (0) 67 (14.7) 39 (16.0) 0.660
Index medium (1–2) 161 (35.2) 83 (34.2) 0.803
Index high ( 3) 229 (50.1) 121 (49.8) 1.000
Empirical antimicrobial therapy
Appropriate therapy 81 (17.7) 18 (7.4) <0.001
Focus of infection
Urinary tract 171 (37.4) 16 (6.6) <0.001
Intra-abdominal 56 (12.3) 93 (38.3) <0.001
IV-catheter 15 (3.3) 17 (7.0) 0.035
Infective endocarditis 61 (13.3) 2 (0.8) <0.001
Respiratory tract 4 (0.9) 14 (5.8) <0.001
Miscellaneous 13 (2.8) 4 (1.6) 0.440
Unknown 137 (30.0) 97 (39.9) 0.009
Antimicrobial resistance
Ampicillin resistant 6 (1.3)b 213 (87.7) <0.001
Vancomycin resistant 7 (1.5)c 3 (1.3)d 1.000
HLGRe 174 (38.2)b 154 (64.4)f <0.001
adata are n (%), except for age, which is years: median [interquartile range, IQR]
and mean [standard deviation, SD].
bn = 455.
cn = 453.
dn = 240.
eHigh level gentamicin resistance.
fn = 239.
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majority of enterococcal bacteraemias were hospital-acquired,
associated with a considerable burden of co-morbidity and
high mortality [6,7,9,12]. We demonstrated a high frequency of
resistant enterococcal strains in hospitalized patients, which
indicates that resistant strains could be hospital-associated
clones. Spread of ampicillin-resistant E. faecium strains has
previously been conﬁrmed in Danish hospitals [4].
Mortality was higher in patients with advanced age,
co-morbidity and hospital-acquired bacteraemia. In addition,
an unknown focus of infection was a predictor of mortality in
patients with E. faecalis bacteraemia. Though it should be
noted that this category also included patients with two or
more likely foci, it underlines the importance of identifying the
underlying focus (e.g. by imaging techniques). Further, we
found that E. faecium bacteraemia was associated with high
mortality compared with E. faecalis bacteraemia, which is in
accordance with two previous studies [6,20]. Virulence
differences between species may be an explanation. A better
efﬁcacy of b-lactam antibiotics administered to most patients
with E. faecalis bacteraemia compared with vancomycin
administered to most patients with E. faecium bacteraemia
may be another explanation.
The frequency of IE was higher than anticipated in E. faecalis
bacteraemia patients (13.3%) and even higher among patients
with a community-acquired infection (25%). As echocardiog-
raphy is not routinely used in all cases of enterococcal
bacteraemia, the frequency of IE may be even higher. This
ﬁnding is of clinical importance: in this high-risk group
echocardiography should be considered in all patients to
optimize antimicrobial therapy, prevent complications and
undertake timely valve replacement. Fernandez Guerrero et al.
[21] reviewed studies examining E. faecalis bacteraemia and
assessed the association between the origin and focus of the
bacteraemia. IE was found in 60 of 1036 patients (5.7%, range
2.4–14%) included in nine studies (55–178 patients). Subgroup
analysis indicated a higher frequency among patients with
community-acquired bacteraemia (12.5%, range 2.7–34%), in
accordance with the present study. In contrast to this study,
polymicrobial bacteraemia was included in most studies.
Polymicrobial bacteraemia is rare in IE [22] and the restriction
to monomicrobial bacteraemia may partly explain a higher
frequency of IE in this study.
Notably few patients received appropriate antimicrobial
therapy within the ﬁrst day after blood was drawn for culture,
TABLE 2. Demographic, clinical and microbiological characteristics distributed according to species and origin of monomicro-
bial enterococcal bacteraemia
Variable
E. faecalis E. faecium
Community
acquired
n (%)
Hospital
acquired
n (%)
Healthcare
associated
n (%)
Community
acquired
n (%)
Hospital
acquired
n (%)
Healthcare
associated
n (%)
Total 144 (100) 209 (100) 104 (100) 18 (100) 207 (100) 18 (100)
Age, median [IQR]a 78 [70–84] 73 [64–80] 71 [60–80] 76 [67–81] 68 [59–75] 77 [65–84]
Male 100 (69.4) 145 (69.4) 79 (76.0) 10 (55.6) 116 (56.0) 14 (77.8)
Speciality
Medicine 122 (84.7)1 105 (50.2)2 77 (74.0) 13 (72.2)1 78 (37.7)2 13 (72.2)
Surgery 17 (11.8)1 74 (35.4) 26 (25.0)3 4 (22.2) 57 (27.5) 3 (16.7)
Intensive care unit 5 (3.5)1 30 (14.4)2 1 (1.0) 1 (5.6)1 72 (34.8) 2 (11.1)
Charlson co-morbidity index
Index low (0) 29 (20.1) 28 (13.4) 10 (9.6)3 7 (38.9)1 30 (14.5) 2 (11.1)
Index medium (1–2) 51 (35.4) 73 (34.9) 37 (35.6) 4 (22.2) 71 (34.3) 8 (44.4)
Index high ( 3) 64 (44.4) 108 (51.7) 57 (54.8) 7 (38.9) 106 (51.2) 8 (44.4)
Empirical antimicrobial therapy
Appropriate therapy 27 (18.8) 34 (16.3) 20 (19.2) 4 (22.2) 14 (6.8) 0 (0.0)
Focus of infection
Urinary tract 60 (41.7) 75 (35.9) 36 (34.6) 2 (11.1) 13 (6.3) 1 (5.6)
Intra-abdominal 9 (6.2)1 30 (14.3) 17 (16.3)3 9 (49.9) 75 (36.2) 9 (49.9)
IV-catheter 0 (0.0)1 11 (5.3) 4 (3.9)3 0 (0.0) 17 (8.2) 0 (0.0)
Infective endocarditis 36 (25.0)1 14 (6.7) 11 (10.6)3 0 (0.0) 1 (0.5) 1 (5.6)
Respiratory tract 1 (0.7) 3 (1.4) 0 (0.0) 1 (5.6) 13 (6.3) 0 (0.0)
Miscellaneous 0 (0.0) 9 (4.3) 4 (3.8) 1 (5.6) 2 (1.0) 1 (5.6)
Unknown 38 (26.4) 67 (32.1) 32 (30.8) 5 (27.8) 86 (41.5) 6 (33.3)
Antimicrobial resistance
Ampicillin resistant 0 (0.0) 5 (2.4) 1 (1.0)b 7 (38.9)1 191 (92.3) 15 (83.3)3
Vancomycin resistant 1 (0.7)c 4 (1.9)d 2 (1.9)b 0 (0.0) 3 (1.5)e 0 (0.0)
HLGRf 28 (19.6)g,1 94 (45.0) 52 (50.5)b, 3 2 (11.8)h,1 145 (71.1)i,2 7 (38.9)
aData are n (%), except for age, which is years: median [interquartile range, IQR].
bn = 103.
cn = 142.
dn = 143.
en = 206.
fHigh level gentamicin resistance.
gn = 208.
hn = 17.
in = 204.
1p <0.05 community-acquired vs. hospital-acquired bacteraemia.
2p <0.05 hospital-acquired vs. healthcare-associated bacteraemia.
3p <0.05 healthcare-associated vs. community-acquired bacteraemia.
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but this did not have a discernible impact on mortality. The low
frequency of appropriate therapy was expected because
cefuroxime has been the preferred drug of choice in patients
presenting with sepsis, and vancomycin is rarely included in
empirical antimicrobial therapy because of a very low preva-
lence of methicillin-resistant Staphylococcus aureus in Denmark.
Previous studies have shown that appropriate antimicrobial
therapy is associated with improved prognosis [6,7,23,24].
However, this study indicates that the ﬁrst-day treatment is
not essential for outcome, as found in some studies on
Gram-negative bacteraemia [25,26]. On the other hand, an
association between outcome and early appropriate antimi-
crobial therapy within the ﬁrst 24 h after diagnosis may be
difﬁcult to demonstrate, especially in a group of patients who
rarely present with severe sepsis [7]. This should not diminish
the clinical signiﬁcance of enterococcal bacteraemia and
additional factors can inﬂuence the efﬁcacy of antibiotics in
vivo. In principle, betalactam antibiotics and glycopeptides are
bactericidal, but the cidal action may be delayed and dependent
at least partly on the immune system, which might be affected
in our patients with a high burden of co-morbidity.
A limitation of the study was the lack of clinical information
on the severity of bacteraemia. We expect clinical attention to
be more meticulous in patients with severe infection and
expect that broad-spectrum coverage is secured more
diligently in patients who are severely ill (confounding by
indication). Additionally, information about the time of initia-
tion of antimicrobial treatment was often imprecise and in
most cases we had to rely on the date of initiation (and not
hour). Similarly, the time of the draw of blood for cultures was
also only recorded by date.
The main strengths of our study were the population-based
design and the large sample size. Data were collected
concurrently with the clinical episodes and independently of
the aims of the current study. The Danish Civil Registration
System enabled complete follow-up.
Conclusion
In conclusion, enterococcal bacteraemia was mainly hospital
acquired and associated with high mortality. The 30-day
mortality was particularly high in patients with E. faecalis
bacteraemia with unknown focus, and identifying the focus
of infection should be given high priority in order to
improve outcome. The high frequency of IE, especially in
community-acquired E. faecalis bacteraemia, raises the ques-
tion of wether echocardiography should be recommended for
all patients with community-acquired E. faecalis bacteraemia.
TABLE 4. Thirty-day mortality in monomicrobial E. faecium
bacteraemia patients
Predictors
30-day
mortality,
n (%)
Unadjusted OR
(95% CIa)
Adjusted ORb
(95% CI)
Total 84 (34.6) – –
Age group (years)
15–64 24 (26.7) 1.0 1.0
65–79 45 (40.5) 1.88 (1.03–3.42) 1.78 (0.95–3.30)
 80 15 (35.7) 1.53 (0.70–3.35) 1.84 (0.80–4.28)
Charlson co-morbidity index
Index low (0) 6 (15.4) 1.0 1.0
Index medium (1–2) 31 (37.4) 3.28 (1.23–8.71) 2.84 (1.04–7.72)
Index high ( 3) 47 (38.8) 3.49 (1.36–8.97) 2.92 (1.10–7.73)
Origin of bacteraemia
Community acquired 2 (11.1) 1.0 1.0
Hospital acquired 76 (36.7) 4.64 (1.04–20.74) 4.29 (0.91–20.31)
Healthcare associated 6 (33.3) 4.00 (0.68–23.41) 3.34 (0.55–20.43)
Focus of infection
Intra-abdominal 30 (32.3) 1.0 1.0
Miscellaneousc 19 (35.2) 1.20 (0.66–2.20) 1.15 (0.55–2.40)
Unknown 35 (36.5) 1.14 (0.56–2.31) 1.16 (0.62–2.16)
Empirical antimicrobial therapy
Appropriate therapy 5 (27.8) 1.0 1.0
Inappropriate therapy 79 (35.1) 1.41 (0.48–4.09) 0.95 (0.30–2.95)
Antimicrobial resistance
Non-HLGR 27 (31.8) 1.0 1.0
HLGRd 56 (36.4) 1.23 (0.70–2.15) 1.07 (0.58–1.97)
Ampicillin susceptible 5 (16.7) 1.0 1.0
Ampicillin resistant 79 (37.1) 2.95 (1.08–8.01) 2.13 (0.67–6.75)
aConﬁdence interval.
bAdjusted for age, Charlson co-morbidity index level, origin, focus of infection and
empirical antimicrobial therapy.
cUrinary tract, IV-catheter, infective endocarditis, respiratory tract, bone, joint,
skin and soft tissue.
dHigh level gentamicin resistance.
TABLE 3. Thirty-day mortality in monomicrobial E. faecalis
bacteraemia patients
Predictors
30-day
mortality
n (%)
Unadjusted OR
(95% CIa)
Adjusted ORb
(95% CI)
Total 98 (21.4) – –
Age group (years)
15–64 14 (12.1) 1.0 1.0
65–79 42 (21.7) 2.01 (1.05–3.87) 2.34 (1.17–4.65)
 80 42 (28.6) 2.91 (0.99–3.16) 3.97 (1.94–8.13)
Charlson co-morbidity index
Index low (0) 7 (10.5) 1.0 1.0
Index medium (1–2) 33 (20.5) 2.21 (0.92–5.28) 1.79 (0.72–4.46)
Index high ( 3) 58 (25.3) 2.90 (1.26–6.72) 2.44 (1.01–5.85)
Origin of bacteraemia
Community acquired 23 (16.0) 1.0 1.0
Hospital acquired 55 (26.3) 1.88 (1.09–3.23) 1.85 (1.02–3.35)
Healthcare associated 20 (19.2) 1.25 (0.65–2.43) 1.33 (0.64–2.71)
Focus of infection
Urinary tract 28 (16.4) 1.0 1.0
Intra-abdominal 14 (25.0) 1.70 (0.82–3.53) 2.04 (0.94–4.46)
Infective endocarditis 5 (8.2) 0.45 (0.17–1.24) 0.62 (0.22–1.75)
Miscellaneousc 5 (15.6) 0.95 (0.34–2.67) 1.01 (0.34–2.98)
Unknown 46 (33.6) 2.58 (1.51–4.42) 3.01 (1.71–5.31)
Empirical antimicrobial therapy
Appropriate therapy 20 (24.7) 1.0 1.0
Inappropriate therapy 78 (20.7) 0.80 (0.45–1.40) 0.80 (0.44–1.46)
Antimicrobial resistance
Non-HLGR 50 (17.8) 1.0 1.0
HLGRd 47 (27.0) 1.71 (1.08–2.69) 1.65 (0.99–2.74)
aConﬁdence interval.
bAdjusted for age, Charlson co-morbidity index level, origin, focus of infection and
empirical antimicrobial therapy.
cBone, joint, skin, soft tissue, IV-catheter and respiratory tract.
dHigh level gentamicin resistance.
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